Antacids Market
Antacids Market Size, Share & Industry Analysis, By Drug Class (Proton Pump Inhibitors, H2 Receptor Blockers, Acid Neutralizers), By Formulation (Tablets, Liquid, Powder), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview:
The global antacids market is projected to grow at a CAGR of 4.8% from 2024 to 2031. The market value is expected to increase from USD YY billion in 2024 to USD YY billion by 2031. Asia-Pacific is currently the fastest-growing region, while North America holds the largest market share. Key metrics include the rising prevalence of gastroesophageal reflux disease (GERD), increasing over-the-counter (OTC) availability of antacids, and growing awareness about digestive health.
The antacids industry is steadily expanding, driven by causes such as changing food patterns, rising stress levels, and an ageing population. The trend of self-medication for minor digestive disorders is also driving market growth, particularly in the OTC sector.
Market Dynamics:
Market Trend: Shift towards natural and organic antacid formulations
The antacids market is experiencing a considerable shift towards natural and organic formulations. Consumers are increasingly looking for alternatives to traditional chemical-based antacids, citing a desire for healthier goods with fewer side effects. This trend is notably visible in the increasing popularity of antacids containing natural calcium carbonate, aloe vera, and herbal extracts. Manufacturers are responding to this trend by creating new product lines that highlight natural ingredients and environmentally friendly production processes. For example, a leading antacid brand reported a 15% rise in sales of its natural formulation line in 2023 over the previous year. This trend is projected to continue, as industry data shows that 30% of antacid users choose natural or organic products.
Market Driver: Rising prevalence of gastroesophageal reflux disease (GERD) and related disorders
The rising prevalence of GERD and other acid-related digestive problems is a key driver of the antacids market. The International Foundation for Gastrointestinal Disorders estimates that GERD affects up to 20% of the adult population in Western countries. In the United States alone, it is estimated that 20% of the population suffers from GERD symptoms at least once each week. The economic burden of GERD is significant, with direct and indirect expenditures in the United States estimated at $12.6 billion per year. Obesity, sedentary lifestyles, and poor dietary habits all contribute to an increase in GERD instances. The ageing population is also an important aspect, as the risk of GERD rises with age. These developments are boosting demand for both over-the-counter (OTC) and prescription antacids, with prescription proton pump inhibitors (PPIs) growing especially rapidly.
Market Restraint: Growing concerns about long-term use of certain antacids
Concerns regarding the potential negative effects of long-term antacid usage, particularly proton pump inhibitors (PPIs), are a substantial barrier to market growth. Recent research has connected chronic PPI usage to an increased risk of renal illness, bone fractures, and some infections. A research published in the Journal of the American Medical Association discovered that PPI users had a 20-50% higher risk of chronic renal disease than nonusers. These discoveries have prompted heightened scrutiny from healthcare providers and regulatory agencies. The United States Food and Drug Administration has issued warnings against the long-term use of PPIs, advising patients to take the lowest effective dose for the shortest time possible. This has led in a change towards more cautious prescribing practices and higher patient awareness, which could have an impact on the prescription antacids market's growth.
Segment Overview:
Proton Pump Inhibitors (PPIs) dominate the global antacids market, accounting for the largest share of revenue.
Proton Pump Inhibitors (PPIs) continue to dominate the antacids industry, owing to their high efficacy in treating acid-related illnesses such as GERD, peptic ulcers, and Zollinger-Ellison syndrome. PPIs function by inhibiting the enzyme that causes acid production in the stomach, offering long-term relief from acid reflux symptoms.
PPIs' dominance is supported by their widespread availability in prescription and over-the-counter formulations. According to the American Gastroenterological Association, PPIs account for more than half of all prescriptions for acid-suppressive drugs. In the OTC market, PPI sales have grown consistently, with retail sales up 3.5% in 2023 compared to the previous year.
Recent improvements in the PPI market have centred on addressing concerns about long-term use and improving patient compliance. For example, a large pharmaceutical company launched a new PPI formulation in 2023 that has a speedier onset of action and a lower risk of medication interactions. This innovation tries to solve some of the problems about standard PPI formulations while preserving its efficacy.
The PPI category has also faced growing competition from generic manufacturers, especially since key brand patents have expired. This has resulted in price reductions and increased accessibility, accelerating market expansion. However, it has increased the demand for branded PPI makers to innovate and differentiate their goods.
Regional Outlook:
Asia-Pacific is the fastest-growing region in the global antacids market, with China and India being the major contributors to regional growth.
The Asia-Pacific antacids market is expanding rapidly, driven by factors such as rising disposable income, increased awareness of digestive health, and shifting dietary habits. The enormous population bases in countries like as China and India, together with increased healthcare expenditure, are opening up significant market expansion potential.
Recent market advancements in Asia-Pacific include the introduction of many new antacid formulations suited to local preferences. For example, in 2023, a big Indian pharmaceutical company launched a new herbal antacid formulation aimed at clients looking for natural solutions.
Key data highlight Asia-Pacific's vast market potential. The Chinese antacids market is expected to develop at a CAGR of 6.2% between 2024 and 2031, exceeding the global average. In India, the OTC antacids segment grew 12% year on year in 2023, reflecting significant customer demand.
Despite its mature market, Japan's antacid sales continue to expand steadily, particularly among the elderly. The Japanese antacids market is distinguished by a significant preference for domestically manufactured brands and novel formulations, such as effervescent pills and chewable versions.
Competitive Intelligence:
The worldwide antacids industry is dominated by both large multinational pharmaceutical corporations and regional players. GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson, and Bayer AG are among the market's leading players. These corporations have carved themselves significant market positions through diverse product portfolios, brand recognition, and global distribution networks.
GlaxoSmithKline dominates the market with its popular brand Tums, but Pfizer's Nexium and Johnson & Johnson's Pepcid are also prominent participants in the OTC antacids area. Rennie, a brand owned by Bayer AG, has a significant presence in Europe and Asia.
Recent market developments include a push for product innovation to meet specific consumer needs. For example, some businesses have produced antacids that include useful ingredients such as probiotics for gut health or calcium for bone strength. There is also an increased emphasis on handy formats, such as chewable tablets and rapid-dissolve formulations.
Mergers and acquisitions have been an important technique for market expansion. In 2022, a multinational pharmaceutical company bought a regional antacid brand to enhance its position in emerging regions.
The antacids market's future prognosis remains favourable, with prospects for growth in growing regions, expanded OTC offers, and the development of novel formulations. Companies are likely to continue investing in R&D to meet unmet needs in acid-related illnesses and enhance treatment outcomes.
Analyst Opinion:
The antacids industry is expected to undergo significant change in the next years, driven by shifting consumer tastes and advances in gastrointestinal treatment. One unique development to watch is the incorporation of digital health technologies with antacid therapy. We foresee the development of smart antacid dispensers that can monitor drug adherence and make personalised dose recommendations based on individual symptom patterns. This combination of digital health and traditional antacid medicines has the potential to transform the management of acid-related illnesses by enhancing treatment efficacy and patient outcomes.
Another notable development is the increased interest in microbiome-friendly antacid formulations. As research continues to reveal the relevance of gut health in general well-being, we anticipate the development of antacids that provide acid relief while also supporting a healthy gut microbiota. This could involve using prebiotics or probiotic cultures that are resistant to stomach acid. Such developments could address concerns about the long-term effects of antacid use on digestive health while also potentially expanding the market to include more health-conscious consumers.
Major Players:
-
GlaxoSmithKline plc
-
Pfizer Inc.
-
Johnson & Johnson
-
Bayer AG
-
Sanofi
-
Reckitt Benckiser Group plc
-
Procter & Gamble
-
Takeda Pharmaceutical Company Limited
-
Abbott Laboratories
-
AstraZeneca plc
Key Developments:
-
In September 2023, GlaxoSmithKline announced a new formulation of its popular antacid brand, combining a blend of natural chemicals to target people looking for alternatives.
-
March 2023: Pfizer announced a collaboration with a digital health firm to create a smart antacid dispenser that includes symptom tracking and dosage optimisation features.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. GlaxoSmithKline plc
5.2. Pfizer Inc.
5.3. Johnson & Johnson
5.4. Bayer AG
5.5. Sanofi
5.6. Reckitt Benckiser Group plc
5.7. Procter & Gamble
5.8. Takeda Pharmaceutical Company Limited
5.9. Abbott Laboratories
5.10. AstraZeneca plc (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards natural and organic antacid formulations
6.1.2. Integration of digital health technologies in antacid therapy
6.1.3. Growing interest in microbiome-friendly antacid formulations
6.2. Market Drivers
6.2.1. Rising prevalence of gastroesophageal reflux disease (GERD) and related disorders
6.2.2. Increasing over-the-counter (OTC) availability of antacids
6.2.3. Growing awareness about digestive health
6.3. Market Restraints
6.3.1. Growing concerns about long-term use of certain antacids
6.3.2. Increasing competition from generic manufacturers
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Proton Pump Inhibitors
7.1.1. Omeprazole
7.1.2. Esomeprazole
7.1.3. Lansoprazole
7.1.4. Others
7.2. H2 Receptor Blockers
7.2.1. Ranitidine
7.2.2. Famotidine
7.2.3. Others
7.3. Acid Neutralizers
7.3.1. Calcium Carbonate
7.3.2. Magnesium Hydroxide
7.3.3. Aluminum Hydroxide
7.3.4. Others
8. BY FORMULATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Tablets
8.1.1. Chewable Tablets
8.1.2. Effervescent Tablets
8.2. Liquid
8.3. Powder
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Antacids Market Segmentation:
By Drug Class:
-
Proton Pump Inhibitors
-
H2 Receptor Blockers
-
Acid Neutralizers
By Formulation:
-
Tablets
-
Liquid
-
Powder
By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511